This study aimed to evaluate the levels of TGFβ, Bcl2, and MAPK mRNA expression in doxorubicin-treated feline kidney cells and naturally occurring CKD-affected kidney tissues, as well as determine the protein expression of TGF-β1 and MAPK in doxorubicin-treated feline kidney cells. The gene discussed is BCL2; the disease is chronic kidney disease.